ISRCTN51612701已完成不适用
Influence of Atorvastatin on coronary calcifications and myocardial perfusion defects in Systemic Lupus Erythematosus patients: a prospective, randomised, double-masked, placebo-controlled study
Polish Ministry of Science and Higher Education (Poland)0 个研究点目标入组 60 人开始时间: 2011年2月18日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Patients aged 20 - 73, either sex
- •2. Fulfilled at least 4 American College of Rheumatology (ACR) classification criteria for SLE
- •3. In stable clinical conditions (no need for immunosuppressive therapy intensification, i.e. current immunosuppressive drug dose increase or introduction of an additional immunosuppressive drug within last 3 months)
排除标准
- •1. Known cancer
- •2. Clinical symptoms of coronary heart disease or heart failure (New York Heart Association [NYHA] III or IV class)
- •3. Renal failure (creatinine clearance less than 30 ml/min)
- •4. Respiratory failure
研究者
相似试验
进行中（未招募）
1 期
MUscle Side-Effects of cholesterol drugs in coronary heart disease patients (MUSE)Coronary heart disease patients With perceived statin Associated muscle symptoms or statin discontinuaton due to muscle symptomsEUCTR2018-004261-14-NOVestre Viken Trust120
已完成
4 期
MUscle Side-Effects of Atorvastatin in Coronary Patients (MUSE) -Follow-up StudyStatin Adverse ReactionNCT04453735Vestre Viken Hospital Trust27
已完成
4 期
Change in Plaque Characteristics With AtorvastatinAcute Coronary SyndromeAtherosclerosisDyslipidemiaNCT00700037Wakayama Medical University70
已完成
不适用
Effect of Pitavastatin on the coronary endothelial dysfunction after PCI with DES (Drug-eluting stent)Patients with coronary artery diseaseJPRN-UMIN000005489Hiroshima University hospital30
已完成
不适用
LDL-c Level Variability and Trained ImmunityCholesterol VariabilityTrained ImmunityNCT05790499Union Hospital, Tongji Medical College, Huazhong University of Science and Technology11